Atlas Trials

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

Clinical trial NCT02815033 · COMPLETED

Trial details

NCT number
NCT02815033
Sponsor
The European Uro-Oncology Group
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Prostate Cancer Metastatic
Start date
2015-07-01
Primary completion
2020-06-01
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.